Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics

CEO Albert Bourla said Pfizer is staring down an expected loss of up to $18 billion in revenue from 2025 through 2030 as patent protections expire.

from Health and Science https://ift.tt/UgLqPnx
https://ift.tt/jwF4JLA
https://ift.tt/ERxnwO5